Background and objectives Although indomethacin has been widely used for the treatment of preterm labor over the past 40 years, there are few reports regarding its pharmacokinetics in pregnant women. Methods This opportunistic study assessed the steady-state pharmacokinetics of indomethacin in pregnant subjects to whom an oral dose of 25 mg every 6 h was prescribed. Indomethacin concentrations in plasma and urine were analyzed by a validated high-performance liquid chromatography method with mass spectrometric detection. Results The mean area under the plasma concentration versus time curve at steady state (AUC ss ) was 1.91 ± 0.53 lgÁh/mL, mean peak plasma concentration (C max ) was 1.02 ± 0.49 lg/mL, and mean time to reach C max (t max ) was 1.3 ± 0.7 h. The mean apparent clearance at steady state was 14.5 ± 5.5 L/h, which is higher than the apparent clearance reported in the literature for non-pregnant subjects. Indomethacin crosses the placenta; the mean fetal/maternal ratio from five sets of cord blood samples collected at delivery was 4.0 ± 1.1. Conclusions Further studies are needed to determine whether any dose adjustments are necessary as a result of the increased clearance of indomethacin during pregnancy.
Introduction
Preterm labor (PTL) and preterm birth (PTB) are major causes of neonatal morbidity and mortality worldwide. Since the onset of labor appears to depend on local synthesis of prostaglandins regulating cervical ripening, formation of myometrial gap junctions, and uterine contractions [1, 2] , the prostaglandin synthetase inhibitor indomethacin has been used to treat PTL since the early 1970s [3] [4] [5] . However, despite the wide use of indomethacin as a tocolytic, there are limited pharmacokinetic data reported for pregnant women to whom indomethacin was prescribed. Most pharmacokinetic data for indomethacin appearing in the literature were obtained in men and nonpregnant females. In general, these reports indicate that absorption of indomethacin is rapid with time to reach maximum concentration (t max ) values between 1 and 2 h, greater than 90 % of the drug is bound to plasma proteins, the drug undergoes O-desmethylation and N-deacylation, drug excreted in the urine is predominantly glucuronidated, and the mean elimination half-life is approximately 6 h [6, 7] .
The use of indomethacin during pregnancy is based on experience gained from trials in which the drug was used to prevent PTL [8] . Nevertheless, the literature lacks pharmacokinetic data that compare exposure to response for indomethacin as a tocolytic. Absorption, distribution, metabolism, and elimination of several drugs are altered during pregnancy due to changes in total body water, metabolism, glomerular filtration rates, and serum albumin concentrations [9] . Therefore, it is important to investigate the relationship between dose, exposure, and response when indomethacin is prescribed in pregnancy, and to see whether subjects receiving the same dose experience different clinical outcomes. If dosing is inadequate, this could lead to low efficacy of the drug or increased risk of maternal and/or fetal/neonatal adverse events. Therefore, the goal of the current investigation was to determine the steady-state pharmacokinetics of indomethacin during pregnancy.
Methods

Subjects
Pregnant females whose providers recommended treatment with indomethacin were eligible for enrollment in this study. Decisions about diagnosis and treatment were made by the subject's own healthcare provider and were independent of participation in this study. To participate, subjects were 18 years of age or older and in a pregnancy window of 12-31 weeks. No enrolled subjects continued to take indomethacin once their gestational age reached 32 weeks. Women were excluded from participation if there was anemia with a hematocrit of less than 28 %, and a prior history of or current medical examination consistent with the presence of clinically significant alterations in hepatic or renal function. All procedures involving human subjects were conducted according to the Declaration of Helsinki and its actual amended version, the International Conference on Harmonization-Good Clinical Practices (ICH-GCP) guidelines. All women were enrolled with written informed consent under a protocol that was approved by the Institutional Review Boards at the University of Texas Medical Branch and the University of Pittsburgh.
Study Protocol
Participants in this opportunistic study received treatment with four daily doses of indomethacin 25 mg capsules (Mylan, Canonsburg, PA, USA) as prescribed by their obstetrician, following a 50-mg loading dose. All women received at least five 25-mg doses prior to the study dose and were therefore assumed to be at steady state at the time the pharmacokinetic study was performed. On the study day, serial blood samples were taken from the antecubital vein immediately prior to and at 0.5, 1, 1.5, 2, 3, 4, and 6 h after indomethacin dosing. Breakfast was provided 1 h post-dose. Urine samples were collected over these same 6 h at 2-or 3-h intervals and stored at -70°C until analysis. Umbilical cord blood and maternal blood samples were collected immediately after delivery in five subjects who gave birth in close proximity to an indomethacin dose. All blood was centrifuged immediately and plasma was stored at -70°C until analysis.
Sample Preparation and Analysis
Indomethacin plasma concentrations were analyzed using a validated high-performance liquid chromatography method with mass spectrometric detection [10] . Briefly, d 4 -indomethacin was used as an internal standard. A 20-lL aliquot of internal standard was added to 200 lL of plasma or urine samples and to calibration standards. Following extraction with chloroform, dried samples were reconstituted in mobile phase (0.05 % formic acid aqueous solution:acetonitrile, 47:53 [v/v]). Analysis was carried out using a Waters Symmetry C 18 column (150 mm 9 4.6 mm, 5 lm) fitted with a Phenomenex C 18 guard column (4 mm 9 3 mm), and a Waters EMD 1000 singlequadrupole mass spectrometer (Milford, MA, USA) with isocratic elution at a flow rate of 1 mL/min and eluent split at a 4:1 ratio, sending 200 lL/min to the mass spectrometer. The lower limit of detection was 3.7 ng/mL in maternal plasma and 2.6 ng/mL in urine. The calibration curves were linear in the range of 14.8-2,970 and 10.5-4,210 ng/mL for plasma and urine, respectively. The accuracy ranged between 90-108 %, and the relative standard deviation (SD) was less than 8 % for inter-and intra-day assays [10] .
Pharmacokinetic Analysis
Pharmacokinetic analyses were conducted using Kinetica software version 5.0 (Thermo Scientific, Waltham, MA, USA). All data were evaluated using a model-independent approach. Plasma concentration versus time data were curve fit using a peeling algorithm to generate initial polyexponential parameter estimates. Final estimates of the terminal elimination rate constant (k z ) were determined from an iterative, non-linear least squares regression algorithm. Individual maximum plasma drug concentration (C max ), minimum plasma drug concentration (C min ), and t max were determined by visual inspection of the plasma concentration versus time profile. The area under the plasma concentration versus time curve at steady state (AUC ss ) was determined using the log-linear trapezoidal rule. For two participants whose plasma sampling was truncated prior to 6 h, the 6-h sample value (C 6 ) was extrapolated from the best-fit curve, and the steady-state AUC from 0 to 6 h was calculated by summation of AUC 0-n ? AUC n-6 , where n represents the last measured time point. The apparent steady-state oral clearance (CL/F ss ) was calculated as the dose divided by the AUC ss , and the mean steady-state drug concentration (C ave ) was calculated as the AUC ss divided by the dosing interval (6 h). Renal clearance (CL R ) was calculated as the total amount of indomethacin excreted unchanged in the urine during the 6-h dosing interval divided by the AUC ss .
Statistical Analysis
Pharmacokinetic data were examined using standard descriptive statistics. Data are presented as mean values ± SD. Regression analysis was performed to assess relationships among pharmacokinetic parameters and other parameters (such as gestational age, ethnicity, smoking status, body mass index [BMI] , and drug interactions identified in the Lexi-Comp Ò Lexi-Interact TM drug interactions database). The Student's t-test was used to compare calculated pharmacokinetic parameters between groups. p-Values less than 0.05 were considered to indicate statistical significance.
Results
Subject Characteristics
Thirty-two pregnant women volunteered to participate in this study. Seven subjects were excluded from full pharmacokinetic analysis due to deviations from the study protocol. Characteristics of the remaining 25 participants are reported in Table 1 . Sixteen subjects were prescribed indomethacin for PTL, eight subjects were treated for short cervix and/or funneling membranes, and one subject took indomethacin for 7 days to treat pain caused by degenerating fibroids during the 14th week of gestation.
Pharmacokinetics
The mean steady-state plasma concentration versus time profile for the 25 subjects is presented in Fig. 1 , and Table 2 presents the mean and median values of the estimated indomethacin pharmacokinetic parameters. The median peak time (1.4 h) was similar to the mean t max value (1.3 h). Maternal and cord blood levels of indomethacin at the time of delivery from five mother-child pairs are reported in Fig. 2 . The mean cord/maternal ratio was 4.0 ± 1.1. Indomethacin excreted unchanged in the urine was sampled and determined for 16 subjects over the 6-h period corresponding to the pharmacokinetic study. The mean amount of drug excreted unchanged in the urine was 280 ± 147 lg, and individual data are presented in Table S1 (see electronic supplementary material [ESM] ).
The design of this study allowed for the determination of plasma indomethacin concentrations over a 6-h dosing interval at steady-state. According to previous reports concerning the pharmacokinetics of indomethacin, plasma concentrations of this drug can be fitted with a two-compartment model, with an initial rapid phase lasting for up to 8 h, followed by a slower b-phase [7] . Alván et al. [7] also stated that indomethacin pharmacokinetic studies limited to 6-or 8-h intervals would not be able to detect the b-phase. This was evident upon examination of the current set of data, where a full b-phase could not be observed within 6 h, thereby precluding the accurate determination of half-life or apparent volume of distribution by area (V b /F). The determination of apparent volume of distribution at steady state (V ss /F) was not feasible without intravenous data [11] . Since cigarette smoking can affect the expression of drug metabolizing enzymes [12] , we investigated the influence of smoking status on the pharmacokinetics of indomethacin in these subjects, but there were no significant differences between the pharmacokinetics of indomethacin in smokers versus non-smokers. The potential influence of gestational age and ethnicity on C max , AUC ss , and CL/F ss were also assessed but no significant correlations were observed within this study group. Likewise, all medications taken concomitantly with indomethacin were evaluated, and interactions that may affect the pharmacokinetics of indomethacin were investigated to seek out correlations with the present data set, but no such relationships were observed. Significant differences between pharmacokinetic parameters based on indication, BMI, and clinical outcome are discussed below.
Discussion
PTL and PTB are the most common causes of perinatal morbidity and mortality. The use of indomethacin during pregnancy is based on experience gained from trials in which the drug was used to treat PTL. In placebo-controlled trials, indomethacin has been shown to be superior to placebo in treating PTL [2, 13] . In fact, it is commonly used as the first-line tocolytic for women who have PTL.
Indomethacin can be administered orally or rectally with a 50-to 100-mg loading dose, followed by 25 mg orally every 4-6 h [14] . In this study, the absorption of indomethacin at steady state in pregnant subjects was found to be rapid, with an average t max value of 1.3 ± 0.7 h. This value is similar to t max data for indomethacin administered to non-pregnant subjects [6] . Table 3 shows that the apparent clearance of indomethacin during pregnancy observed in this study (14.5 ± 5.5 L/h) is greater than the steady-state clearance reported for non-pregnant subjects (ranging from 6.5 to 9.8 L/h). Due to the higher clearance of indomethacin observed during pregnancy, four daily 25-mg doses of the drug result in the same C ave of indomethacin in pregnant subjects as only three daily 25-mg doses in the non-pregnant subjects studied by Baber et al. [15] . The C ave value in pregnant subjects was also 37 % lower than the C ave reported following three daily 25-mg doses to the participants in the study by Alván et al. [7] , who more closely match the age and body weight of the pregnant subjects in the present study. The observed increases in apparent clearance of indomethacin in pregnant women may be due to differences in absorption, increased urinary excretion, decreased albumin concentrations, or more extensive hepatic metabolism of the drug during pregnancy. Although physiological changes associated with pregnancy may affect the absorption of certain drugs [9] , the complete absorption of indomethacin observed in previous studies [6] suggests that this is less likely to be a significant factor. Less than 5 % of indomethacin is excreted unchanged in the urine [6] . In the present study, the mean CL R was only 0.15 ± 0.07 L/h (n = 16), and the mean cumulative urinary excretion of unchanged indomethacin within the 6-h steady-state pharmacokinetic study was 280 ± 147 lg. This represents just over 1 % of the administered dose, and Traeger et al. [16] reported only slightly higher urinary excretion of indomethacin in pregnant women versus non-pregnant women. Reduced albumin concentrations during pregnancy could lead to an increase in the fraction of unbound indomethacin, which may lead to increased clearance of the drug [17] . Indomethacin is extensively metabolized to phase I metabolites (such as O-desmethylindomethacin) and phase II metabolites (including indomethacin acyl glucuronide, O-desmethylindomethacin acyl glucuronide, and O-desmethylindomethacin ether glucuronide) [18] . The biotransformation of indomethacin to O-desmethylindomethacin is primarily catalyzed by cytochrome P450 (CYP) 2C9 [19] . The activity of this enzyme appears to be increased approximately 1.5-fold in pregnancy [20] , which is similar to the fold increase in the apparent clearance of indomethacin observed in the pregnant subjects participating in this study. It has been suggested that pregnancy-related increases in estradiol concentrations may affect the activity of CYP2C9 [21] .
Among the factors mentioned above affecting the clearance of indomethacin in pregnancy, increased biotransformation may be the most substantial. However, placental transfer of indomethacin should not be ignored as significant concentrations of the drug were detected in cord blood samples. Therefore, the rate of drug transfer to the fetal compartment also has an impact on the overall clearance rate of indomethacin from the maternal circulation. Nevertheless, whether the increased clearance observed in pregnant subjects would require that a higher dose be administered to manage PTL cannot be concluded from this study.
The cord blood data collected at the time of delivery for five mother-child pairs in this study revealed a cord-tomaternal plasma ratio of 4.0 ± 1.1. Following a single oral dose of 2.5 mg/kg administered to the mother shortly before delivery (175 mg if 70 kg body weight is assumed), Traeger et al. [16] observed cord-to-maternal ratios ranging from about 0.16-1.6, depending on the time since the administration of the drug. They observed that the ratio was near one after 4-5 h. Similarly, Moise et al. [22] observed a cord-to-maternal ratio near unity about 6 h after a single 50-mg oral dose.
The higher cord-to-maternal ratio observed in the present study is likely higher than these other reported values for two reasons. First, the present study was at steady state, whereas the other studies determined the cord-to-maternal ratio after a single dose. The estimated half-life of indomethacin in premature and neonatal infants is nearly seven times longer than the half-life of indomethacin in adults [16] . This slower clearance from the fetus may be due to reduced capacity for biotransformation reactions in the developing fetus and/or the pharmacological effects of indomethacin itself in reducing the fetal urinary output [22] . Since the drug is cleared more slowly from the fetus, more drug can accumulate over time, which may explain the higher cord-to-maternal ratios observed with steadystate dosing. Table 3 Comparison of CL/F ss and C ave data from this investigation in pregnant subjects receiving 25 mg of indomethacin orally every 6 h with C ave and CL/F ss data reported in the literature for non-pregnant subjects Study Subjects Age (years) Weight (kg) Dose (mg) C ave (lg/mL) CL/F ss (L/h) Present study 25 pregnant females 26.2 ± 6.5 79.7 ± 22.9 25 (every 6 h) 0.32 ± 0.09 14.5 ± 5.5
Alván et al. [7] 5 males 22-29 65-93 25 (every 8 h) 0.51 ± 0.14 6.5 ± 1.6
Baber et al. [15] 5 males ? 15 non-pregnant females 55. Values are presented as mean ± SD, where available CL/F ss apparent steady-state oral clearance, C ave average steady-state drug concentration, NR not reported a NR, but based on the reported weight-normalized value for clearance (0.207 L/h/kg) the mean weight is estimated to be approximately 50 kg A second factor that may influence cord-to-maternal ratios is the amount of time between the last dose and delivery, which was as much as 51 h in this investigation, but only between 1 and 9 h in previously published studies [16, 22] . Figure 2a shows that both maternal and fetal levels of indomethacin tended to decrease as a function of the time since the last dose was given prior to delivery. Nevertheless, there is no clear dependence of fetal-tomaternal ratios on the time post-drug administration. Figure 2b shows the relationships between cord blood levels and both the time since the last dose and the total duration of dosing. The highest cord blood concentration was observed in the case where the drug had been dosed for 14 consecutive days prior to delivery, and only 8 h had passed since the last dose. Although there are only five data points, there is agreement in the trends of decreased cord blood concentrations with decreased dosing duration and increased time between dose and delivery.
One subject (#14 in Table S1 ) appeared to be an outlier, having a lower degree of drug exposure and higher apparent oral clearance in comparison to the other study participants. No available auxiliary data stand out as an explanation for this observation. Although subject #14 reported smoking half a pack of cigarettes per day, and smoking has been shown to alter the expression of some drug metabolizing enzymes [12] , the data from other smokers who participated in this study do not suggest any specific influence of smoking status on the pharmacokinetic profiles overall. It is possible that subject #14 is a fast metabolizer by virtue of pharmacogenetic differences that were not investigated as part of this study.
Although there were no specific trends in the pharmacokinetic parameters as a function of gestational age, the one subject who was studied in the 14th week of pregnancy did have the lowest C min value and an AUC ss value that was 25 % lower than the average AUC ss from the other subjects (gestational ages 22-31 weeks). Nevertheless, with only one participant studied in early pregnancy, one cannot make any conclusions regarding the influence of gestational age on the pharmacokinetics of indomethacin.
Clinical data in Tables S1, S2 , and S3 (see ESM) were assessed for differences between the pharmacokinetic parameters of subjects for whom indomethacin was prescribed for PTL versus short cervix. Although there was substantial variation in the duration of dosing, those receiving indomethacin for short cervix and/or funneling membranes took the medication for a significantly longer period (30.5 ± 30.2 days) than those subjects to whom the drug was prescribed for PTL (11.9 ± 11.1 days; p \ 0.05). In addition, the apparent clearance of indomethacin at steady state was significantly higher in subjects being treated for short cervix (17.7 ± 8.1 L/h) than in subjects treated for PTL (12.7 ± 3.0 L/h; p \ 0.05).
Among the subjects treated for PTL, the time between the last dose of indomethacin and delivery was at least 11 days for 12 subjects, who had an average BMI of 28.2 ± 5.7 kg/m 2 . The three subjects treated for PTL who delivered within 3 days of their last dose had a significantly higher BMI (39.1 ± 12.8 kg/m 2 ; p \ 0.05). Similarly, among those subjects taking indomethacin for short cervix and/or funneling membranes, the time between the last dose and delivery was at least 29 days for five subjects, who had an average BMI of 27.9 ± 5.8 kg/m 2 . Three subjects treated for short cervix and/or funneling membranes delivered within 3 days of their last dose, and the average BMI of these subjects trended higher (37.5 ± 6.6 kg/m 2 ; p = 0.07). Nevertheless, there were no significant differences in the C max , AUC ss , or CL/F ss values of those subjects for whom delivery was or was not delayed for at least 72 h, 7 days, or 30 days since the last dose. The mean C max value of subjects treated for PTL for whom delivery was delayed at least 30 days (1.36 ± 0.54 lg/mL; n = 7) did tend to be higher than the C max of those for whom delivery was not delayed at least 30 days (0.95 ± 0.31 lg/mL; n = 8) but this was not statistically significant (p = 0.09). The lack of correlations between pharmacokinetic parameters and clinical outcomes in this study are similar to what had been reported for rheumatoid arthritis patients. Baber et al. [15] compared the steady-state pharmacokinetics of indomethacin in patients previously classified as responders or nonresponders to indomethacin therapy but no significant differences in the pharmacokinetic profiles of responders versus non-responders were observed.
Oligohydramnios, or low amniotic fluid, is a potential complication of indomethacin use during pregnancy. This was observed in four pregnancies (see Tables S2 and S3 in the ESM). For these four subjects, the average t max value from the steady-state pharmacokinetic study was 0.63 ± 0.25 h. For the other 20 subjects, the mean t max was significantly delayed (1.42 ± 0.70 h; p \ 0.05); however, there were no significant differences in AUC ss , C max , C min , or CL/F ss between the groups of subjects with or without oligohydramnios. Kirshon et al. [23] observed that prolonged indomethacin therapy in utero can cause a decrease in fetal urine output, which can lead to oligohydramnios; however, in this study there was no significant difference in the number of days indomethacin was dosed between the subjects with and without oligohydramnios (13.5 ± 5.8 vs.
19.2 ± 23.2 days, respectively).
Conclusions
The steady-state apparent clearance of indomethacin in pregnancy was shown to be higher than reported clearance data for indomethacin administered to non-pregnant subjects. This may be due to both alterations in the activity of maternal drug metabolizing enzymes during pregnancy and significant maternal-to-fetal drug transfer. Clearance was also higher in subjects treated for short cervix compared with those treated for PTL. Oligohydramnios was observed in four cases, but there was no correlation with maternal drug exposure (AUC ss , the number of doses received, or their product). The increased clearance of the drug in pregnant subjects compared with non-pregnant subjects may not mean that a higher maternal dose should be given. In light of the concentrations of drug observed in cord blood samples, one must consider the fetal consequences of an increase in maternal dose. Additional clinical data are needed to determine whether any dose adjustments would be necessary.
